\BOOKMARK [-1][-]{part.1}{I Notes}{}% 1
\BOOKMARK [0][-]{chapter.1}{Introduction}{part.1}% 2
\BOOKMARK [1][-]{section.1.1}{Genetics vs Genomics}{chapter.1}% 3
\BOOKMARK [2][-]{subsection.1.1.1}{Genetics}{section.1.1}% 4
\BOOKMARK [2][-]{subsection.1.1.2}{Genomics}{section.1.1}% 5
\BOOKMARK [2][-]{subsection.1.1.3}{Differences}{section.1.1}% 6
\BOOKMARK [2][-]{subsection.1.1.4}{Role of computational biology}{section.1.1}% 7
\BOOKMARK [1][-]{section.1.2}{Human Genomics - the Basis}{chapter.1}% 8
\BOOKMARK [2][-]{subsection.1.2.1}{Genetic Make-Up}{section.1.2}% 9
\BOOKMARK [2][-]{subsection.1.2.2}{Inherited variants' relevance}{section.1.2}% 10
\BOOKMARK [2][-]{subsection.1.2.3}{Differences in Genetic Make-Up, an example}{section.1.2}% 11
\BOOKMARK [2][-]{subsection.1.2.4}{Acquired DNA aberrations}{section.1.2}% 12
\BOOKMARK [1][-]{section.1.3}{Experimental techniques to detect variants/aberrations}{chapter.1}% 13
\BOOKMARK [2][-]{subsection.1.3.1}{Cariotyping}{section.1.3}% 14
\BOOKMARK [1][-]{section.1.4}{Sequence capture for cancer genomics}{chapter.1}% 15
\BOOKMARK [2][-]{subsection.1.4.1}{Single End \(SE\) and Paired End \(PE\) reads}{section.1.4}% 16
\BOOKMARK [0][-]{chapter.2}{Coverage}{part.1}% 17
\BOOKMARK [1][-]{section.2.1}{Local Coverage and Allelic Fraction}{chapter.2}% 18
\BOOKMARK [2][-]{subsection.2.1.1}{Mapped reads}{section.2.1}% 19
\BOOKMARK [1][-]{section.2.2}{When to increase the intended coverage of a NGS assay}{chapter.2}% 20
\BOOKMARK [1][-]{section.2.3}{Interpreting Pair Orientations}{chapter.2}% 21
\BOOKMARK [2][-]{subsection.2.3.1}{Inversion}{section.2.3}% 22
\BOOKMARK [2][-]{subsection.2.3.2}{Tandem duplication}{section.2.3}% 23
\BOOKMARK [2][-]{subsection.2.3.3}{Inverted duplication}{section.2.3}% 24
\BOOKMARK [1][-]{section.2.4}{Summary}{chapter.2}% 25
\BOOKMARK [0][-]{chapter.3}{Genetic Fingerprinting}{part.1}% 26
\BOOKMARK [1][-]{subsection.3.0.1}{Variants used for genetic testing}{chapter.3}% 27
\BOOKMARK [1][-]{section.3.1}{SNPs features}{chapter.3}% 28
\BOOKMARK [2][-]{subsection.3.1.1}{Hardy-Weinberg equilibrium and Minor Allele frequency}{section.3.1}% 29
\BOOKMARK [2][-]{subsection.3.1.2}{Minor Allele Frequency}{section.3.1}% 30
\BOOKMARK [2][-]{subsection.3.1.3}{Haplotype Blocks}{section.3.1}% 31
\BOOKMARK [2][-]{subsection.3.1.4}{Other SNPs features}{section.3.1}% 32
\BOOKMARK [2][-]{subsection.3.1.5}{Number of SNPs to select}{section.3.1}% 33
\BOOKMARK [2][-]{subsection.3.1.6}{Some questions}{section.3.1}% 34
\BOOKMARK [2][-]{subsection.3.1.7}{Further considerations}{section.3.1}% 35
\BOOKMARK [1][-]{section.3.2}{Building a SNP-based genetic test}{chapter.3}% 36
\BOOKMARK [2][-]{subsection.3.2.1}{Implementation of a probabilistic test}{section.3.2}% 37
\BOOKMARK [2][-]{subsection.3.2.2}{Example 1: Cell line passages}{section.3.2}% 38
\BOOKMARK [2][-]{subsection.3.2.3}{Individual's Relatedness \(genotype-distance\)}{section.3.2}% 39
\BOOKMARK [2][-]{subsection.3.2.4}{Example 3: Cancer supscettibility test}{section.3.2}% 40
\BOOKMARK [2][-]{subsection.3.2.5}{Genetic structure of the human population}{section.3.2}% 41
\BOOKMARK [0][-]{chapter.4}{IGV \(Integrative Genomics Viewer\)}{part.1}% 42
\BOOKMARK [1][-]{section.4.1}{Main characteristics}{chapter.4}% 43
\BOOKMARK [2][-]{subsection.4.1.1}{Igvtools}{section.4.1}% 44
\BOOKMARK [2][-]{subsection.4.1.2}{Session Files}{section.4.1}% 45
\BOOKMARK [1][-]{section.4.2}{Some of the main utilizations}{chapter.4}% 46
\BOOKMARK [2][-]{subsection.4.2.1}{RNA-seq alignments}{section.4.2}% 47
\BOOKMARK [2][-]{subsection.4.2.2}{Study of variants}{section.4.2}% 48
\BOOKMARK [1][-]{section.4.3}{Exercise}{chapter.4}% 49
\BOOKMARK [2][-]{subsection.4.3.1}{Task B}{section.4.3}% 50
\BOOKMARK [0][-]{chapter.5}{Tumor Evolution Studies via NGS data}{part.1}% 51
\BOOKMARK [1][-]{section.5.1}{Tumor evolution}{chapter.5}% 52
\BOOKMARK [1][-]{section.5.2}{From sketches to sequencing data evolution information}{chapter.5}% 53
\BOOKMARK [2][-]{subsection.5.2.1}{Tumor evolution and heterogeneity}{section.5.2}% 54
\BOOKMARK [2][-]{subsection.5.2.2}{Useful feature from NGS data}{section.5.2}% 55
\BOOKMARK [2][-]{subsection.5.2.3}{Allelic Fraction \(AF\) properties}{section.5.2}% 56
\BOOKMARK [1][-]{section.5.3}{Coverage and AF properties}{chapter.5}% 57
\BOOKMARK [1][-]{section.5.4}{Computing Beta}{chapter.5}% 58
\BOOKMARK [1][-]{section.5.5}{Global vs Local Estimates of admixture}{chapter.5}% 59
\BOOKMARK [1][-]{section.5.6}{A challenging case \(PR-2741}{chapter.5}% 60
\BOOKMARK [0][-]{chapter.6}{Tumor evolution studies \(continued\)}{part.1}% 61
\BOOKMARK [1][-]{section.6.1}{Recalls from the previous lecture}{chapter.6}% 62
\BOOKMARK [1][-]{section.6.2}{Ploidy and purity correction on 2\(TN\) data}{chapter.6}% 63
\BOOKMARK [0][-]{chapter.7}{Tumor evolution studies via NGS data: SNVs-based methods}{part.1}% 64
\BOOKMARK [1][-]{section.7.1}{Rationale of somatic point mutation based assays}{chapter.7}% 65
\BOOKMARK [1][-]{section.7.2}{TPES \(Tumor Purity Estimation\)}{chapter.7}% 66
\BOOKMARK [1][-]{section.7.3}{How many SNVs are needed to assess tumor purity?}{chapter.7}% 67
\BOOKMARK [1][-]{section.7.4}{Comparison between purity callers}{chapter.7}% 68
\BOOKMARK [1][-]{section.7.5}{Pros and Cons of SNVs-based tumor purity assessment}{chapter.7}% 69
\BOOKMARK [0][-]{chapter.8}{Liquid biopsies in oncology}{part.1}% 70
\BOOKMARK [1][-]{section.8.1}{Liquid vs Tissue biopsies}{chapter.8}% 71
\BOOKMARK [1][-]{section.8.2}{Issues in the interpretation of cfDNA data}{chapter.8}% 72
\BOOKMARK [2][-]{subsection.8.2.1}{Normalization on tumor content}{section.8.2}% 73
\BOOKMARK [2][-]{subsection.8.2.2}{Quantity of input material}{section.8.2}% 74
\BOOKMARK [1][-]{section.8.3}{SNV detection in liquid biopsies}{chapter.8}% 75
\BOOKMARK [1][-]{section.8.4}{Requirements depend on the application}{chapter.8}% 76
\BOOKMARK [1][-]{section.8.5}{Whole genome vs targeted sequencing}{chapter.8}% 77
\BOOKMARK [1][-]{section.8.6}{Take-home message}{chapter.8}% 78
\BOOKMARK [0][-]{chapter.9}{Epigenetic profiling of cell-free DNA}{part.1}% 79
\BOOKMARK [1][-]{section.9.1}{Introduction}{chapter.9}% 80
\BOOKMARK [1][-]{section.9.2}{DNA methylation}{chapter.9}% 81
\BOOKMARK [1][-]{section.9.3}{How is DNA methylation measured?}{chapter.9}% 82
\BOOKMARK [1][-]{section.9.4}{Tissue-specific vs disease-specific DNA markers}{chapter.9}% 83
\BOOKMARK [1][-]{section.9.5}{DNA methylation based liquid biopsy}{chapter.9}% 84
\BOOKMARK [2][-]{subsection.9.5.1}{Workflow}{section.9.5}% 85
\BOOKMARK [2][-]{subsection.9.5.2}{CCGA study}{section.9.5}% 86
\BOOKMARK [2][-]{subsection.9.5.3}{Deconvolution approaches}{section.9.5}% 87
\BOOKMARK [1][-]{section.9.6}{Targeted panel approaches for tumor content estimation}{chapter.9}% 88
\BOOKMARK [-1][-]{part.2}{II Papers}{}% 89
\BOOKMARK [0][-]{chapter.10}{Role of non-coding sequence variants in cancer}{part.2}% 90
\BOOKMARK [1][-]{section.10.1}{Abstract}{chapter.10}% 91
\BOOKMARK [2][-]{subsection.10.1.1}{Introduction}{section.10.1}% 92
\BOOKMARK [1][-]{section.10.2}{Genomic sequence variants}{chapter.10}% 93
\BOOKMARK [1][-]{section.10.3}{Non-coding element annotation}{chapter.10}% 94
\BOOKMARK [2][-]{subsection.10.3.1}{Cis regulatory regions}{section.10.3}% 95
\BOOKMARK [2][-]{subsection.10.3.2}{Distal regulatory elements}{section.10.3}% 96
\BOOKMARK [2][-]{subsection.10.3.3}{RNA-seq}{section.10.3}% 97
\BOOKMARK [2][-]{subsection.10.3.4}{Transcribed pseudogenes}{section.10.3}% 98
\BOOKMARK [2][-]{subsection.10.3.5}{Evolutionary conservation}{section.10.3}% 99
\BOOKMARK [1][-]{section.10.4}{Roles for somatic variants in cancer}{chapter.10}% 100
\BOOKMARK [2][-]{subsection.10.4.1}{Gain of TF-binding sites}{section.10.4}% 101
\BOOKMARK [2][-]{subsection.10.4.2}{Fusion events due to genomic rearrangements}{section.10.4}% 102
\BOOKMARK [2][-]{subsection.10.4.3}{ncRNAs and their binding sites}{section.10.4}% 103
\BOOKMARK [2][-]{subsection.10.4.4}{Role of pseudogenes in modulating the expression of a parental gene}{section.10.4}% 104
\BOOKMARK [1][-]{section.10.5}{Roles for germline variants in cancer}{chapter.10}% 105
\BOOKMARK [2][-]{subsection.10.5.1}{Promoter mutations}{section.10.5}% 106
\BOOKMARK [2][-]{subsection.10.5.2}{SNPs in enhancers}{section.10.5}% 107
\BOOKMARK [2][-]{subsection.10.5.3}{Variants in introns}{section.10.5}% 108
\BOOKMARK [2][-]{subsection.10.5.4}{SNPs in ncRNA and their binding sites}{section.10.5}% 109
\BOOKMARK [2][-]{subsection.10.5.5}{Others}{section.10.5}% 110
\BOOKMARK [1][-]{section.10.6}{Interplay between germline and somatic variants}{chapter.10}% 111
\BOOKMARK [1][-]{section.10.7}{Computational methods for identifying variants}{chapter.10}% 112
\BOOKMARK [1][-]{section.10.8}{Experimental approaches for functional validation}{chapter.10}% 113
\BOOKMARK [0][-]{chapter.11}{Advances in understanding cancer genomics through second-generation sequencing}{part.2}% 114
\BOOKMARK [1][-]{section.11.1}{Abstract}{chapter.11}% 115
\BOOKMARK [2][-]{subsection.11.1.1}{Introduction}{section.11.1}% 116
\BOOKMARK [1][-]{section.11.2}{Cancer-specific consideration}{chapter.11}% 117
\BOOKMARK [2][-]{subsection.11.2.1}{Characteristics of cancer samples for genomic analysis}{section.11.2}% 118
\BOOKMARK [2][-]{subsection.11.2.2}{Structural variability of cancer genomes}{section.11.2}% 119
\BOOKMARK [1][-]{section.11.3}{Experimental approaches}{chapter.11}% 120
\BOOKMARK [2][-]{subsection.11.3.1}{Whole genome sequencing}{section.11.3}% 121
\BOOKMARK [2][-]{subsection.11.3.2}{Exome sequencing}{section.11.3}% 122
\BOOKMARK [2][-]{subsection.11.3.3}{Transcriptome sequencing}{section.11.3}% 123
\BOOKMARK [1][-]{section.11.4}{Detecting classes of genome alterations}{chapter.11}% 124
\BOOKMARK [2][-]{subsection.11.4.1}{Somatic nucleotide substitutions and small insertion and deletion mutations}{section.11.4}% 125
\BOOKMARK [2][-]{subsection.11.4.2}{Copy number}{section.11.4}% 126
\BOOKMARK [2][-]{subsection.11.4.3}{Chromosomal rearrangements}{section.11.4}% 127
\BOOKMARK [2][-]{subsection.11.4.4}{Microbe-discovery methods}{section.11.4}% 128
\BOOKMARK [1][-]{section.11.5}{Computational issues}{chapter.11}% 129
\BOOKMARK [2][-]{subsection.11.5.1}{Alignment and assembly}{section.11.5}% 130
\BOOKMARK [2][-]{subsection.11.5.2}{mutations detection}{section.11.5}% 131
\BOOKMARK [2][-]{subsection.11.5.3}{Validation of mutation and rearrangement calls}{section.11.5}% 132
\BOOKMARK [0][-]{chapter.12}{Integrative genomics viewer}{part.2}% 133
\BOOKMARK [1][-]{section.12.1}{Introduction}{chapter.12}% 134
\BOOKMARK [0][-]{chapter.13}{Tumour heterogeneity and resistance to cancer therapies}{part.2}% 135
\BOOKMARK [1][-]{section.13.1}{Abstract}{chapter.13}% 136
\BOOKMARK [2][-]{subsection.13.1.1}{Introduction}{section.13.1}% 137
\BOOKMARK [1][-]{section.13.2}{Causes of intratumoral heterogeneity}{chapter.13}% 138
\BOOKMARK [2][-]{subsection.13.2.1}{Genomic instability}{section.13.2}% 139
\BOOKMARK [2][-]{subsection.13.2.2}{The clonal evolution and selection hypothesis}{section.13.2}% 140
\BOOKMARK [1][-]{section.13.3}{The spectrum of tumour heterogeneity}{chapter.13}% 141
\BOOKMARK [2][-]{subsection.13.3.1}{Spatial heterogeneity}{section.13.3}% 142
\BOOKMARK [2][-]{subsection.13.3.2}{Temporal heterogeneity}{section.13.3}% 143
\BOOKMARK [1][-]{section.13.4}{Noninvasive monitoring of heterogeneity}{chapter.13}% 144
\BOOKMARK [2][-]{subsection.13.4.1}{Analysis of ctDNA}{section.13.4}% 145
\BOOKMARK [1][-]{section.13.5}{Overcoming heterogeneity}{chapter.13}% 146
\BOOKMARK [0][-]{chapter.14}{Unravelling the clonal hierarchy of somatic genomic aberrations}{part.2}% 147
\BOOKMARK [1][-]{section.14.1}{Introduction}{chapter.14}% 148
\BOOKMARK [2][-]{subsection.14.1.1}{Abstract}{section.14.1}% 149
\BOOKMARK [2][-]{subsection.14.1.2}{Background}{section.14.1}% 150
\BOOKMARK [1][-]{section.14.2}{Results}{chapter.14}% 151
\BOOKMARK [2][-]{subsection.14.2.1}{Clonality assessment of aberrations from sequencing reads}{section.14.2}% 152
\BOOKMARK [2][-]{subsection.14.2.2}{Inferring the order of mutations in a tumour sample}{section.14.2}% 153
\BOOKMARK [2][-]{subsection.14.2.3}{In silico and in situ experimental validation}{section.14.2}% 154
\BOOKMARK [2][-]{subsection.14.2.4}{Comparative analysis reveals different mechanisms of tumour deregulation}{section.14.2}% 155
\BOOKMARK [2][-]{subsection.14.2.5}{Clonal hierarchy of genomic aberrations}{section.14.2}% 156
\BOOKMARK [1][-]{section.14.3}{Materials and methods}{chapter.14}% 157
\BOOKMARK [2][-]{subsection.14.3.1}{CLONET pipeline}{section.14.3}% 158
\BOOKMARK [2][-]{subsection.14.3.2}{CLONET on exome and targeted sequencing data}{section.14.3}% 159
\BOOKMARK [2][-]{subsection.14.3.3}{Expected distribution of the allelic fraction of a genomic segment}{section.14.3}% 160
\BOOKMARK [2][-]{subsection.14.3.4}{Estimated proportion of neutral reads for a genomic segment}{section.14.3}% 161
\BOOKMARK [2][-]{subsection.14.3.5}{From neutral to non-aberrant reads}{section.14.3}% 162
\BOOKMARK [2][-]{subsection.14.3.6}{From aberrant reads to aberrant cells}{section.14.3}% 163
\BOOKMARK [2][-]{subsection.14.3.7}{Uncertainty assessment and its propagation to clonality estimates}{section.14.3}% 164
\BOOKMARK [2][-]{subsection.14.3.8}{Clonality of bi-allelic deletion}{section.14.3}% 165
\BOOKMARK [0][-]{chapter.15}{TPES: timor purity estimation from SNVs}{part.2}% 166
\BOOKMARK [1][-]{section.15.1}{Abstract}{chapter.15}% 167
\BOOKMARK [2][-]{subsection.15.1.1}{Introduction}{section.15.1}% 168
\BOOKMARK [1][-]{section.15.2}{Materials and methods}{chapter.15}% 169
\BOOKMARK [0][-]{chapter.16}{SNP panel identification assay \(SPIA\): a genetic-based assay for the identification of cell lines}{part.2}% 170
\BOOKMARK [1][-]{section.16.1}{Abstract}{chapter.16}% 171
\BOOKMARK [2][-]{subsection.16.1.1}{Introduction}{section.16.1}% 172
\BOOKMARK [1][-]{section.16.2}{Material and methods}{chapter.16}% 173
\BOOKMARK [2][-]{subsection.16.2.1}{Genotype distance}{section.16.2}% 174
\BOOKMARK [2][-]{subsection.16.2.2}{SNP panel selection procedure}{section.16.2}% 175
\BOOKMARK [2][-]{subsection.16.2.3}{SPIA probabilistic test on cell line genotype distance}{section.16.2}% 176
